Skip navigation

Navigate Medical Affairs Complexities and Shine Light on R&D Compliance to Propel Scientific Exchange

December 5-6, 2018
  • Philadelphia, PA

CBI’s Bio/Pharma Compliance Congress on Non-Promotional Activities offers an unparalleled agenda delivered by the industry’s leading experts. During this meeting, navigate medical affairs complexities and shine light on R&D compliance to propel scientific exchange in a time of increased scrutiny. Collaborate with your peers to zero in on prevailing industry approaches to advance your company’s compliance efforts and return with clear
strategies to navigate the gray area between clinical and
commercial to ensure compliance enterprise-wide.

CLE, CPE &
CCB Credits
Available! Pending Approval

HOT TOPICS ON THE FOREFRONT:

  • Off-Label Communication —
    Regulatory Updates and Actions for 2017
  • Keep Pulse on the Latest Enforcement Activities and
    Areas of Oversight
  • Explore the Evolving Role of Medical Affairs during a
    Time of Transformative Change
  • Dissemination of Scientific Information —
    What Does the Future Hold?
  • Zero In on the Fine Line between Commercial and Clinical to
    Optimize Compliance with Internal Counterparts
  • Enhance Monitoring Efforts to Ensure a Compliant Fleet of MSLs
  • Navigate CME Regulation and Explore Expectations for
    Industry to Remain Compliant
  • Ramp up Clinical and R&D Oversight to Maintain Compliance
  • Clinical Trial Compliance — Pre, During and Post
  • Examine Compliance Considerations for the Exchange of
    HEOR and Real-World Evidence

Bio/Pharma Compliance Congress on Non-Promotional Activities

Navigate Medical Affairs Complexities and Shine Light on R&D Compliance to Propel Scientific Exchange

CBI’s Bio/Pharma Compliance Congress on Non-Promotional Activities offers an unparalleled agenda delivered by the industry’s leading experts. During this meeting, navigate medical affairs complexities and shine light on R&D compliance to propel scientific exchange in a time of increased scrutiny. Collaborate with your peers to zero in on prevailing industry approaches to advance your company’s compliance efforts and return with clear
strategies to navigate the gray area between clinical and
commercial to ensure compliance enterprise-wide.

CLE, CPE &
CCB Credits
Available! Pending Approval

HOT TOPICS ON THE FOREFRONT:

  • Off-Label Communication —
    Regulatory Updates and Actions for 2017
  • Keep Pulse on the Latest Enforcement Activities and
    Areas of Oversight
  • Explore the Evolving Role of Medical Affairs during a
    Time of Transformative Change
  • Dissemination of Scientific Information —
    What Does the Future Hold?
  • Zero In on the Fine Line between Commercial and Clinical to
    Optimize Compliance with Internal Counterparts
  • Enhance Monitoring Efforts to Ensure a Compliant Fleet of MSLs
  • Navigate CME Regulation and Explore Expectations for
    Industry to Remain Compliant
  • Ramp up Clinical and R&D Oversight to Maintain Compliance
  • Clinical Trial Compliance — Pre, During and Post
  • Examine Compliance Considerations for the Exchange of
    HEOR and Real-World Evidence